Stem Cell Research Institute Co., Ltd. issued a total of 1,564 new stock acquisition rights to directors on July 22, 2026, corresponding to approximately 156,400 shares. The purpose is to enhance performance and secure human resources.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7096","jir_company_name":"Stem Cell Research Institute Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/7096-20260722-01.pdf","jir_short_summary":"Stem Cell Research Institute Co., Ltd. issued a total of 1,564 new stock acquisition rights to directors on July 22, 2026, corresponding to approximately 156,400 shares. The purpose is to enhance performance and secure human resources.","jir_summary":"### Details of Stock Option Issuance\nStem Cell Research Institute Co., Ltd. issued the first and second stock acquisition rights on July 22, 2026. The first issuance comprised 514 rights (equivalent to 51,400 shares), and the second issuance comprised 1,050 rights (equivalent to 105,000 shares), with an exercise price of 1,000 yen. These rights were granted to directors and employees, aiming to improve performance and secure human resources. The exercise period is from July 22, 2026, to July 31, 2034, and from August 1, 2026, to July 31, 2032, respectively. There will be no increase in capital stock due to these issuances, as they are to be exercised using treasury stock.\n\n### Future Business Activities and Impact\nThis stock option issuance is a measure aimed at boosting employee morale and attracting talented personnel. The dilutive effect on shares is limited, as part of a strategy to enhance corporate value. The recipients are directors and executive officers, and proper exercise within the exercise periods could positively influence future stock prices and business performance.","jir_financial_highlights":"Total number of stock acquisition rights issued: 514 (1st issuance) \u30fb 1,050 (2nd issuance) (Unknown)\nNumber of shares targeted: 51,400 shares (1st issuance) \u30fb 105,000 shares (2nd issuance) (Unknown)\nExercise price: 1,000 yen (Unknown)","jir_category":"","jir_hashtags":"#StemCellResearchInstitute, #StockOption, #Japa neseStocks","jir_key_figures":"Total number of stock acquisition rights issued: 514 (1st issuance), 1,050 (2nd issuance)\nNumber of targeted shares: 51,400 shares (1st issuance), 105,000 shares (2nd issuance)\nExercise price: 1,000 yen","jir_meta_title":"\u3010Stem Cell Research Institute\u3011Stock Option Issuance | July 22, 2026","jir_meta_description":"Stem Cell Research Institute Co., Ltd. issued stock acquisition rights on July 22, 2026, implementing capital measures aimed at improving employee morale and corporate value.","jir_og_title":"\u3010Stem Cell Research Institute\u3011Stock Option Issuance | July 22, 2026","jir_og_description":"Stem Cell Research Institute Co., Ltd. issued stock acquisition rights on July 22, 2026, aiming to boost employee morale and enhance corporate value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":0,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-86709","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n